You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
白雲山(00874.HK)收到廣東藥品監督管理局核准簽發的《藥品生產許可證》
格隆匯 01-15 18:03

格隆匯1月15日丨白雲山(00874.HK)公吿,近日,廣州白雲山醫藥集團股份有限公司(以下簡稱“公司”)全資子公司廣州白雲山中一藥業有限公司(以下簡稱“中一藥業”)收到廣東省藥品監督管理局核准簽發的《藥品生產許可證》,同意中一藥業核減生產線以及新增生產線。

同意中一藥業核減在生產地址“廣州市從化明珠工業園創業大道南4號(除K1棟)”生產車間“星洲製造部”中生產線“F棟生產線”。核減在原批准信息“接受廣州白雲山奇星藥業有限公司委託生產華佗再造丸(國藥準字Z44020748)、益婦止血丸(國藥準字Z10970108)、金丹丸(國藥準字B20020525)”基礎上涉及受託生產地址“廣州市從化明珠工業園創業大道南4號(除K1棟)”生產車間“星洲製造部”中“F棟生產線”。

在原委託批准信息“接受廣州白雲山奇星藥業有限公司委託生產清熱散結片(國藥準字Z44022794),受託生產地址為:廣州市從化明珠工業園創業大道南4號(除K1棟)、廣州市黃埔區雲埔一路32號、廣州市番禺區南村鎮七星崗”基礎上,在生產地址“廣州市從化明珠工業園創業大道南4號(除K1棟)”生產車間“星洲製造部”新增受託生產線“D棟”,委託有效期至2025年9月21日。

本次中一藥業核減生產線以及新增生產線,有利於公司優化資源配置,繼續保持穩定的生產能力,滿足市場需求。本次獲得《藥品生產許可證》,對公司當期業績無重大影響。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account